{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:29:10Z","timestamp":1779337750086,"version":"3.51.4"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009053","name":"Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","award":["IA\/E\/17\/1\/503663"],"award-info":[{"award-number":["IA\/E\/17\/1\/503663"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology","doi-asserted-by":"publisher","award":["CRG\/2023\/001776"],"award-info":[{"award-number":["CRG\/2023\/001776"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000964","name":"Arthritis National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001428","name":"Amity University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117376","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:38:34Z","timestamp":1759419514000},"page":"117376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P3","title":["Cancer-associated transporters: Molecular drivers and drug delivery gateways"],"prefix":"10.1016","volume":"242","author":[{"given":"Aqsa","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhrajit","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8557-5780","authenticated-orcid":false,"given":"Shinjinee","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117376_b0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/j.2040-4603.2012.tb00424.x","article-title":"Role of monosaccharide transport proteins in carbohydrate assimilation, distribution, metabolism, and homeostasis","volume":"2","author":"Cura","year":"2012","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.bcp.2025.117376_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2021.107816","article-title":"Transporter engineering for the development of cyanobacteria as cell factories: a text analytics guided survey","volume":"54","author":"Sengupta","year":"2022","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.bcp.2025.117376_b0015","doi-asserted-by":"crossref","unstructured":"S.S. Pao, I.T. Paulsen, M.H. Saier, Major Facilitator Superfamily, Microbiology and Molecular Biology Reviews 62 (1998) 1 LP \u2013 34. https:\/\/doi.org\/10.1128\/MMBR.62.1.1-34.1998.","DOI":"10.1128\/MMBR.62.1.1-34.1998"},{"key":"10.1016\/j.bcp.2025.117376_b0020","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/dmd.113.056176","article-title":"Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?","volume":"42","author":"Callaghan","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2025.117376_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/life12060897","article-title":"Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein","volume":"12","author":"Karthika","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.bcp.2025.117376_b0030","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1038\/sj.onc.1203015","article-title":"Regulation of p53 in response to DNA damage","volume":"18","author":"Lakin","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117376_b0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.10.043","article-title":"A global map of p53 transcription-factor binding sites in the human genome","volume":"124","author":"Wei","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117376_b0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncb2173","article-title":"p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs","volume":"13","author":"Chang","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2025.117376_b0045","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s12935-022-02831-4","article-title":"Transition of amyloid\/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness","volume":"22","author":"Sengupta","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2025.117376_b0050","article-title":"Potential role of p53 deregulation in modulating immune responses in human malignancies: a paradigm to develop immunotherapy","author":"Chauhan","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2025.117376_b0055","doi-asserted-by":"crossref","unstructured":"W.S. el-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, B. Vogelstein, WAF1, a potential mediator of p53 tumor suppression., Cell 75 (1993) 817\u2013825. https:\/\/doi.org\/10.1016\/0092-8674(93)90500-p.","DOI":"10.1016\/0092-8674(93)90500-P"},{"key":"10.1016\/j.bcp.2025.117376_b0060","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cmet.2018.07.005","article-title":"A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3","volume":"28","author":"Tajan","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2025.117376_b0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/978-981-13-8023-5_50","article-title":"Targeting Taurine Transporter (TauT) for Cancer Immunotherapy of p53 Mutation Mediated Cancers - Molecular Basis and Preclinical Implication","volume":"1155","author":"Han","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bcp.2025.117376_b0070","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ncb1724","article-title":"p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation","volume":"10","author":"Kawauchi","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2025.117376_b0075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1126\/science.1346476","article-title":"Modulation of activity of the promoter of the human MDR1 gene by Ras and p53","volume":"255","author":"Chin","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.117376_b0080","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1172\/JCI9290","article-title":"Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells","volume":"105","author":"Sullivan","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2025.117376_b0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ijc.10226","article-title":"Cancer chemoresistance: the relationship between p53 and multidrug transporters","volume":"98","author":"Bush","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117376_b0090","first-page":"58","article-title":"Multidrug resistance associated proteins in multidrug resistance., Chin","volume":"31","author":"Sodani","year":"2012","journal-title":"J. Cancer"},{"key":"10.1016\/j.bcp.2025.117376_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020203","article-title":"ASCT2 and LAT1 Contribution to the Hallmarks of Cancer: from a Molecular Perspective to Clinical translation","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2025.117376_b0100","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/bjc.2014.178","article-title":"Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer","volume":"110","author":"Toyoda","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117376_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/cdd.2017.105","article-title":"p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis","author":"Ghosh","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2025.117376_b0110","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.261017","article-title":"p53 amyloid pathology is correlated with higher cancer grade irrespective of the mutant or wild-type form","author":"Sengupta","year":"2023","journal-title":"J Cell Sci 136"},{"key":"10.1016\/j.bcp.2025.117376_b0115","doi-asserted-by":"crossref","first-page":"27716","DOI":"10.1074\/jbc.C100121200","article-title":"Transcriptional repression by p53 through direct binding to a novel DNA element","volume":"276","author":"Johnson","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117376_b0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41419-021-03497-y","article-title":"Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane","volume":"12","author":"Phatak","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2025.117376_b0125","doi-asserted-by":"crossref","first-page":"11037","DOI":"10.1073\/pnas.94.20.11037","article-title":"p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents","volume":"94","author":"Thottassery","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2025.117376_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109450","article-title":"Nuclear factor-\u03baB signaling inhibitors revert multidrug-resistance in breast cancer cells","author":"Abdin","year":"2021","journal-title":"Chem Biol Interact 340"},{"key":"10.1016\/j.bcp.2025.117376_b0135","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.4161\/15384101.2014.949083","article-title":"The transcription factor p53: not a repressor, solely an activator","volume":"13","author":"Fischer","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2025.117376_b0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/cdd.2017.174","article-title":"Mechanisms of transcriptional regulation by p53","volume":"25","author":"Sullivan","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2025.117376_b0145","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/ncomms3935","article-title":"Tumour-associated mutant p53 drives the Warburg effect","author":"Zhang","year":"2013","journal-title":"Nat Commun 4"},{"key":"10.1016\/j.bcp.2025.117376_b0150","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1158\/0008-5472.CAN-03-0846","article-title":"The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression","volume":"64","author":"Schwartzenberg-Bar-Yoseph","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117376_b0155","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1111\/febs.14577","article-title":"Glucose transporters in cancer \u2013 from tumor cells to the tumor microenvironment","volume":"285","author":"Ancey","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2025.117376_b0160","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1038\/oncsis.2014.16","article-title":"Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53\/NAD(H)-dependent and (ii) p53-independent pathways","volume":"3","author":"Allison","year":"2014","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bcp.2025.117376_b0165","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4161\/cbt.12.11.18140","article-title":"Tumor cell metabolism: an integral view","volume":"12","author":"Romero-Garcia","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2025.117376_b0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","article-title":"Cellular fatty acid metabolism and cancer","volume":"18","author":"Currie","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2025.117376_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.728759","article-title":"Glucose Metabolism and Glucose Transporters in Breast Cancer","volume":"9","author":"Shin","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2025.117376_b0180","first-page":"641","article-title":"Expression and putative role of mitochondrial transport proteins in cancer, Biochimica et Biophysica Acta (BBA) -","author":"Lytovchenko","year":"1858","journal-title":"Bioenergetics"},{"key":"10.1016\/j.bcp.2025.117376_b0185","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/15384101.2015.1120930","article-title":"Lactate promotes glutamine uptake and metabolism in oxidative cancer cells","volume":"15","author":"P\u00e9rez-Escuredo","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2025.117376_b0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12957-016-0769-9","article-title":"Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer","volume":"14","author":"Li","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.bcp.2025.117376_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101928","article-title":"PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer","volume":"42","author":"Hong","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2025.117376_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/S0145-2126(96)00086-0","article-title":"P53 protein expression in human multidrug-resistant CEM lymphoblasts","volume":"21","author":"Rafki","year":"1997","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcp.2025.117376_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076085","article-title":"Relevance of Sugar Transport across the Cell Membrane","volume":"24","author":"Carb\u00f3","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117376_b0210","doi-asserted-by":"crossref","unstructured":"A. Godoy, V. Ulloa, F. Rodr\u00edguez, K. Reinicke, A.J. Ya\u00f1ez, M. de los A. Garc\u00eda, R.A. Medina, M. Carrasco, S. Barberis, T. Castro, F. Mart\u00ednez, X. Koch, J.C. Vera, M.T. Poblete, C.D. Figueroa, B. Peruzzo, F. P\u00e9rez, F. Nualart, Differential subcellular distribution of glucose transporters GLUT1\u20136 and GLUT9 in human cancer: Ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues, J Cell Physiol 207 (2006) 614\u2013627. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/jcp.20606.","DOI":"10.1002\/jcp.20606"},{"key":"10.1016\/j.bcp.2025.117376_b0215","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.molcel.2017.07.014","article-title":"Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport","volume":"67","author":"Nagarajan","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2025.117376_b0220","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-023-08535-w","article-title":"The role of GLUT2 in glucose metabolism in multiple organs and tissues","volume":"50","author":"Sun","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bcp.2025.117376_b0225","doi-asserted-by":"crossref","first-page":"68381","DOI":"10.18632\/oncotarget.20266","article-title":"SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117376_b0230","doi-asserted-by":"crossref","first-page":"R786","DOI":"10.1152\/ajpregu.90694.2008","article-title":"Differential expression of GLUT2 in pancreatic islets and kidneys of New and Old World nonhuman primates","volume":"296","author":"Kramer","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.bcp.2025.117376_b0235","first-page":"2683","article-title":"Expression of facilitative glucose transporters in gastric tumors","volume":"46","author":"Noguchi","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.bcp.2025.117376_b0240","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2147\/CMAR.S190591","article-title":"The novel sugar transporter SLC50A1 as a potential serum-based diagnostic and prognostic biomarker for breast cancer","volume":"11","author":"Wang","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bcp.2025.117376_b0245","doi-asserted-by":"crossref","first-page":"23780","DOI":"10.18632\/oncotarget.25267","article-title":"p53 and metabolism: from mechanism to therapeutics","volume":"9","author":"Simabuco","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117376_b0250","first-page":"45","article-title":"Biology of glucose metabolization in cancer cells, Journal of Oncological","volume":"3","author":"Fadaka","year":"2017","journal-title":"Sciences"},{"key":"10.1016\/j.bcp.2025.117376_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030317","article-title":"Tumor Energy Metabolism and potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment","volume":"11","author":"Fan","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2025.117376_b0260","article-title":"Regulation of Cancer Metabolism by Deubiquitinating Enzymes: the Warburg effect","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117376_b0265","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ncb1724","article-title":"p53 regulates glucose metabolism through an IKK-NF-\u03baB pathway and inhibits cell transformation","volume":"10","author":"Kawauchi","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2025.117376_b0270","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1093\/nar\/gkw523","article-title":"Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks","volume":"44","author":"Fischer","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.117376_b0275","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/onc.2016.502","article-title":"Census and evaluation of p53 target genes","volume":"36","author":"Fischer","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117376_b0280","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fendo.2018.00124","article-title":"The p53 Tumor Suppressor in the Control of Metabolism and Ferroptosis","volume":"9","author":"Gnanapradeepan","year":"2018","journal-title":"Front Endocrinol (lausanne)"},{"key":"10.1016\/j.bcp.2025.117376_b0285","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.3390\/cimb44120414","article-title":"Exploring and Identifying Candidate Genes and Genomic Regions Related to Economically Important Traits in Hanwoo cattle","volume":"44","author":"Naserkheil","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.bcp.2025.117376_b0290","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2018.11.011","article-title":"p53 Represses the Mevalonate Pathway to Mediate Tumor suppression","volume":"176","author":"Moon","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117376_b0295","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","article-title":"Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway","volume":"148","author":"Freed-Pastor","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117376_b0300","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.molcel.2014.04.024","article-title":"Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation","volume":"54","author":"Zhou","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2025.117376_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2021.100839","article-title":"Mechanistic roles of mutant p53 governing lipid metabolism","volume":"83","author":"Loughran","year":"2022","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.bcp.2025.117376_b0310","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41416-019-0451-4","article-title":"Lipid metabolism in cancer cells under metabolic stress","volume":"120","author":"Munir","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117376_b0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020273","article-title":"Iron as a Central Player and Promising Target in Cancer Progression","volume":"20","author":"Jung","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117376_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010095","article-title":"Iron Metabolism in Cancer","volume":"20","author":"Wang","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117376_b0325","volume":"13","author":"Lahalle","year":"2021","journal-title":"The p53 Pathway and Metabolism: the Tree That Hides the Forest"},{"key":"10.1016\/j.bcp.2025.117376_b0330","doi-asserted-by":"crossref","unstructured":"A. Molchadsky, I. Shats, N. Goldfinger, M. Pevsner-Fischer, M. Olson, A. Rinon, E. Tzahor, G. Lozano, D. Zipori, R. Sarig, V. Rotter, p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner., PLoS One 3 (2008) e3707. https:\/\/doi.org\/10.1371\/journal.pone.0003707.","DOI":"10.1371\/journal.pone.0003707"},{"key":"10.1016\/j.bcp.2025.117376_b0335","doi-asserted-by":"crossref","first-page":"33911","DOI":"10.1074\/jbc.M806432200","article-title":"Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest","volume":"283","author":"Zhang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117376_b0340","article-title":"Transferrin receptor 1 nuclear translocation facilitates tumor progression via p53-mediated chromatin interactions and genome-wide alterations","volume":"10","author":"Hou","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2025.117376_b0345","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.celrep.2014.02.042","article-title":"Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function","volume":"7","author":"Shen","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2025.117376_b0350","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","volume":"520","author":"Jiang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117376_b0355","doi-asserted-by":"crossref","unstructured":"N. Zhao, A.-S. Zhang, A.M. Wortham, S. Jue, M.D. Knutson, C.A. Enns, The Tumor Suppressor, P53, Decreases the Metal Transporter, ZIP14., Nutrients 9 (2017). https:\/\/doi.org\/10.3390\/nu9121335.","DOI":"10.3390\/nu9121335"},{"key":"10.1016\/j.bcp.2025.117376_b0360","article-title":"Metabolism of Amino Acids in Cancer","author":"Wei","year":"2020","journal-title":"Front Cell Dev Biol 8"},{"key":"10.1016\/j.bcp.2025.117376_b0365","doi-asserted-by":"crossref","unstructured":"X.H. Lowman, E.A. Hanse, Y. Yang, M.B. Ishak Gabra, T.Q. Tran, H. Li, M. Kong, p53 Promotes Cancer Cell Adaptation to Glutamine Deprivation by Upregulating Slc7a3 to Increase Arginine Uptake, Cell Rep 26 (2019). https:\/\/doi.org\/10.1016\/j.celrep.2019.02.037.","DOI":"10.1016\/j.celrep.2019.02.037"},{"key":"10.1016\/j.bcp.2025.117376_b0370","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3892\/mmr.2020.11321","article-title":"Significance of taurine transporter (TauT) in homeostasis and its layers of regulation (Review)","volume":"22","author":"Baliou","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bcp.2025.117376_b0375","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1093\/emboj\/cdf656","article-title":"Taurine as a constituent of mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial diseases","volume":"21","author":"Suzuki","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2025.117376_b0380","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M205939200","article-title":"Transcriptional repression of taurine transporter gene (TauT) by p53 in renal cells","volume":"277","author":"Han","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117376_b0385","article-title":"Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth","volume":"14","author":"Tombari","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117376_b0390","doi-asserted-by":"crossref","first-page":"14240","DOI":"10.1074\/jbc.M117.798405","article-title":"The glutamate\/cystine antiporter SLC7A11\/xCT enhances cancer cell dependency on glucose by exporting glutamate","volume":"292","author":"Koppula","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117376_b0395","article-title":"The Role of Cystine\/Glutamate Antiporter SLC7A11\/xCT in the Pathophysiology of Cancer., Front","volume":"12","author":"Jyotsana","year":"2022","journal-title":"Oncol"},{"key":"10.1016\/j.bcp.2025.117376_b0400","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-023-00532-z","article-title":"Specific regulation of BACH1 by the hotspot mutant p53R175H reveals a distinct gain-of-function mechanism","volume":"4","author":"Su","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.bcp.2025.117376_b0405","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2025.117376_b0410","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00280-002-0551-2","article-title":"Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells","volume":"51","author":"Tsang","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117376_b0415","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41419-018-0507-z","article-title":"p53 attenuates acetaminophen-induced hepatotoxicity by regulating drug-metabolizing enzymes and transporter expression","volume":"9","author":"Sun","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2025.117376_b0420","article-title":"Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53","volume":"58","author":"Wang","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117376_b0425","doi-asserted-by":"crossref","first-page":"14240","DOI":"10.1073\/pnas.1017536108","article-title":"Wild-type p53 controls cell motility and invasion by dual regulation of MET expression","volume":"108","author":"Hwang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2025.117376_b0430","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/bjc.1996.316","article-title":"p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer","volume":"74","author":"Linn","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117376_b0435","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccr.2013.03.022","article-title":"Mutant p53 prolongs NF-\u03baB activation and promotes chronic inflammation and inflammation-associated colorectal cancer","volume":"23","author":"Cooks","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2025.117376_b0440","doi-asserted-by":"crossref","first-page":"13213","DOI":"10.1074\/jbc.M414646200","article-title":"Differential Regulation of MDR1 Transcription by the p53 Family members: ROLE OF THE DNA BINDING DOMAIN *","volume":"280","author":"Johnson","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117376_b0445","doi-asserted-by":"crossref","DOI":"10.1038\/sj.onc.1210862","article-title":"\u0394Np73\u03b1 regulates MDR1 expression by inhibiting p53 function","volume":"27","author":"Vilgelm","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117376_b0450","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.645593","article-title":"Mechanisms of Cellular Senescence: Cell Cycle arrest and Senescence Associated Secretory Phenotype","volume":"9","author":"Kumari","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2025.117376_b0455","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030420","article-title":"Role of p53 in the Regulation of Cellular Senescence","volume":"10","author":"Mijit","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2025.117376_b0460","doi-asserted-by":"crossref","first-page":"br10","DOI":"10.1091\/mbc.E21-05-0262","article-title":"Riboflavin transporter SLC52A1, a target of p53, suppresses cellular senescence by activating mitochondrial complex II","volume":"32","author":"Nagano","year":"2021","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bcp.2025.117376_b0465","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1038\/s41467-019-10566-6","article-title":"Mechanistic basis of L-lactate transport in the SLC16 solute carrier family","volume":"10","author":"Bosshart","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117376_b0470","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/cts.12551","article-title":"Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy","volume":"11","author":"Fisel","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bcp.2025.117376_b0475","doi-asserted-by":"crossref","first-page":"8413","DOI":"10.2147\/IJGM.S337615","article-title":"Prognostic Value of SLC16A3(MCT4) in Lung Adenocarcinoma and its Clinical significance","volume":"14","author":"Xue","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.bcp.2025.117376_b0480","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3389\/fphar.2018.00842","article-title":"Clinical significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer","author":"Svoboda","year":"2018","journal-title":"Front Pharmacol 9"},{"key":"10.1016\/j.bcp.2025.117376_b0485","doi-asserted-by":"crossref","unstructured":"C.B. Levy, A.C. Stumbo, A.P.D. Ano Bom, E.A. Portari, Y. Cordeiro, J.L. Silva, C. V De Moura-Gallo, Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors., Int J Biochem Cell Biol 43 (2011) 60\u201364. https:\/\/doi.org\/10.1016\/j.biocel.2010.10.017.","DOI":"10.1016\/j.biocel.2010.10.017"},{"key":"10.1016\/j.bcp.2025.117376_b0490","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1021\/acs.biochem.9b00796","article-title":"Prion-like p53 Amyloids in Cancer","volume":"59","author":"Navalkar","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2025.117376_b0495","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-022-00317-7","article-title":"p53 amyloid aggregation in cancer: function, mechanism, and therapy","volume":"11","author":"Li","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2025.117376_b0500","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.258316","article-title":"Direct evidence of cellular transformation by prion-like p53 amyloid infection","author":"Navalkar","year":"2021","journal-title":"J Cell Sci 134"},{"key":"10.1016\/j.bcp.2025.117376_b0505","doi-asserted-by":"crossref","DOI":"10.1038\/cdd.2017.105","article-title":"p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis","author":"Ghosh","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2025.117376_b0510","doi-asserted-by":"crossref","first-page":"28152","DOI":"10.1074\/jbc.M112.340638","article-title":"Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer","author":"Ano Bom","year":"2012","journal-title":"J Biol Chem 287"},{"key":"10.1016\/j.bcp.2025.117376_b0515","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.bbrc.2012.11.130","article-title":"Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity","volume":"430","author":"Lasagna-Reeves","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2025.117376_b0520","article-title":"Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches","author":"Alvarado-Ortiz","year":"2020","journal-title":"Front Cell Dev Biol 8"},{"key":"10.1016\/j.bcp.2025.117376_b0525","article-title":"Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches, Front Cell","volume":"8","author":"Alvarado-Ortiz","year":"2021","journal-title":"Dev. Biol."},{"key":"10.1016\/j.bcp.2025.117376_b0530","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.emboj.7601930","article-title":"The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases","volume":"27","author":"Winklhofer","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2025.117376_b0535","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/onc.2012.334","article-title":"Mutant p53 gain-of-function induces epithelial\u2013mesenchymal transition through modulation of the miR-130b\u2013ZEB1 axis","volume":"32","author":"Dong","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117376_b0540","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.259500","article-title":"Oncogenic gain of function due to p53 amyloids occurs through aberrant alteration of cell cycle and proliferation","author":"Navalkar","year":"2022","journal-title":"J Cell Sci 135"},{"key":"10.1016\/j.bcp.2025.117376_b0545","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.258316","article-title":"Direct evidence of cellular transformation by prion-like p53 amyloid infection","author":"Navalkar","year":"2021","journal-title":"J Cell Sci 134"},{"key":"10.1016\/j.bcp.2025.117376_b0550","doi-asserted-by":"crossref","unstructured":"S. Almasi, Y. El Hiani, Exploring the Therapeutic Potential of Membrane Transport Proteins: Focus on Cancer and Chemoresistance., Cancers (Basel) 12 (2020). https:\/\/doi.org\/10.3390\/cancers12061624.","DOI":"10.3390\/cancers12061624"},{"key":"10.1016\/j.bcp.2025.117376_b0555","doi-asserted-by":"crossref","unstructured":"M.F. Carusela, J. Miguel Rubi, Computational Model for Membrane Transporters. Potential Implications for Cancer., Front Cell Dev Biol 9 (2021) 642665. https:\/\/doi.org\/10.3389\/fcell.2021.642665.","DOI":"10.3389\/fcell.2021.642665"},{"key":"10.1016\/j.bcp.2025.117376_b0560","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.apsb.2019.12.005","article-title":"Targeting uptake transporters for cancer imaging and treatment","volume":"10","author":"Zhang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2025.117376_b0565","doi-asserted-by":"crossref","unstructured":"Y. Yao, Y. Zhou, L. Liu, Y. Xu, Q. Chen, Y. Wang, S. Wu, Y. Deng, J. Zhang, A. Shao, Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance., Front Mol Biosci 7 (2020) 193. https:\/\/doi.org\/10.3389\/fmolb.2020.00193.","DOI":"10.3389\/fmolb.2020.00193"},{"key":"10.1016\/j.bcp.2025.117376_b0570","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/jbm.a.36515","article-title":"A degradable triple temperature-, pH-, and redox-responsive drug system for cancer chemotherapy","volume":"106","author":"Yu","year":"2018","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.bcp.2025.117376_b0575","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2016.11.020","article-title":"Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance","volume":"245","author":"Braunov\u00e1","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2025.117376_b0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0142-9612(99)00125-8","article-title":"Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin a in polyalkylcyanoacrylate nanoparticles","volume":"21","author":"Soma","year":"2000","journal-title":"Biomaterials"},{"key":"10.1016\/j.bcp.2025.117376_b0585","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/carcin\/bgr016","article-title":"COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63\/73 in colorectal cancer","volume":"32","author":"Sui","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2025.117376_b0590","doi-asserted-by":"crossref","unstructured":"S. Zhang, N. Guo, G. Wan, T. Zhang, C. Li, Y. Wang, Y. Wang, Y. Liu, pH and redox dual-responsive nanoparticles based on disulfide-containing poly(\u03b2-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer., J Nanobiotechnology 17 (2019) 109. https:\/\/doi.org\/10.1186\/s12951-019-0540-9.","DOI":"10.1186\/s12951-019-0540-9"},{"key":"10.1016\/j.bcp.2025.117376_b0595","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.biomaterials.2009.09.048","article-title":"The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance","volume":"31","author":"Patil","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.bcp.2025.117376_b0600","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2217\/nnm.11.93","article-title":"P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells","volume":"7","author":"Navarro","year":"2012","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.bcp.2025.117376_b0605","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s11671-019-3143-3","article-title":"Cancer Cell Membrane decorated Silica Nanoparticle Loaded with miR495 and Doxorubicin to Overcome Drug Resistance for Effective Lung Cancer Therapy","volume":"14","author":"He","year":"2019","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.bcp.2025.117376_b0610","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14050894","article-title":"Application of CRISPR-Cas9 System to Study Biological Barriers to Drug delivery","volume":"14","author":"He","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2025.117376_b0615","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10637-020-00924-3","article-title":"First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors","volume":"38","author":"Okano","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2025.117376_b0620","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2007.14.9807","article-title":"Phase III Study of Valspodar (PSC 833) combined with Paclitaxel and Carboplatin Compared with Paclitaxel and Carboplatin Alone in patients with Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer","volume":"26","author":"Lhomm\u00e9","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.117376_b0625","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in patients with Advanced Cancer","volume":"29","author":"Halford","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117376_b0630","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2018.00243","article-title":"The Human SLC7A5 (LAT1): the Intriguing Histidine\/Large Neutral Amino Acid Transporter and its Relevance to Human Health","volume":"6","author":"Scalise","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.bcp.2025.117376_b0635","doi-asserted-by":"crossref","unstructured":"Y. Kanai, H. Segawa, K. i Miyamoto, H. Uchino, E. Takeda, H. Endou, Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98)., J Biol Chem 273 (1998) 23629\u201323632. https:\/\/doi.org\/10.1074\/jbc.273.37.23629.","DOI":"10.1074\/jbc.273.37.23629"},{"key":"10.1016\/j.bcp.2025.117376_b0640","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.564809","article-title":"Review of the Correlation of LAT1 with Diseases: Mechanism and Treatment","volume":"8","author":"Zhang","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.bcp.2025.117376_b0645","first-page":"21","article-title":"Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment., World J Gastrointest","volume":"9","author":"Hayashi","year":"2017","journal-title":"Oncol"},{"key":"10.1016\/j.bcp.2025.117376_b0650","first-page":"93","article-title":"Potential Biomarker of L-type Amino Acid Transporter 1 in Breast Cancer Progression., Nucl Med","volume":"45","author":"Liang","year":"2011","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.bcp.2025.117376_b0655","first-page":"2943","article-title":"The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells","volume":"26","author":"Kim","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bcp.2025.117376_b0660","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1254\/jphs.08232FP","article-title":"Establishment and characterization of mammalian cell lines stably expressing human L-type amino acid transporters","volume":"108","author":"Morimoto","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2025.117376_b0665","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1210\/er.2001-0029","article-title":"The Sodium\/Iodide Symporter (NIS): Characterization, Regulation, and Medical significance","volume":"24","author":"Doh\u00e1n","year":"2003","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bcp.2025.117376_b0670","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.2967\/jnumed.116.186833","article-title":"Norepinephrine Transporter as a Target for Imaging and Therapy","volume":"58","author":"Pandit-Taskar","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bcp.2025.117376_b0675","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/CCO.0b013e328356da72","article-title":"Glucose transporters in cancer metabolism","volume":"24","author":"Adekola","year":"2012","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bcp.2025.117376_b0680","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/cpt.418","article-title":"Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease","volume":"100","author":"Jones","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117376_b0685","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215344","article-title":"Glycolysis-Related SLC2A1 is a potential Pan-Cancer Biomarker for Prognosis and Immunotherapy","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2025.117376_b0690","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1038\/s41467-023-39401-9","article-title":"SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells","volume":"14","author":"Yan","year":"2023","journal-title":"Nat. Commun."},{"issue":"Pt 1","key":"10.1016\/j.bcp.2025.117376_b0695","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/bj3500219","article-title":"The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells","volume":"350","author":"Dimmer","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2025.117376_b0700","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JND-140021","article-title":"Mutations in the Mitochondrial Citrate Carrier SLC25A1 are Associated with Impaired Neuromuscular Transmission","volume":"1","author":"Chaouch","year":"2014","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.bcp.2025.117376_b0705","doi-asserted-by":"crossref","first-page":"32434","DOI":"10.1074\/jbc.M503152200","article-title":"Identification of dicarboxylate carrier Slc25a10 as malate transporter in de novo fatty acid synthesis","volume":"280","author":"Mizuarai","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117376_b0710","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMc1513610","article-title":"SLC25A32 Mutations and Riboflavin-Responsive Exercise Intolerance","volume":"374","author":"Schiff","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117376_b0715","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1208\/s12248-017-0165-6","article-title":"ABCB6, an ABC Transporter Impacting Drug Response and Disease","volume":"20","author":"Boswell-Casteel","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2025.117376_b0720","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2019.00208","article-title":"Inhibitors of Human ABCG2: from Technical Background to recent Updates with Clinical Implications","volume":"10","author":"Toyoda","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117376_b0725","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1177\/002215540104900805","article-title":"SLC26A2 (Diastrophic Dysplasia Sulfate Transporter) is Expressed in developing and Mature Cartilage but also in Other Tissues and Cell Types","volume":"49","author":"Haila","year":"2001","journal-title":"Journal of Histochemistry & Cytochemistry"},{"key":"10.1016\/j.bcp.2025.117376_b0730","article-title":"SLC2A3 promotes tumor progression through lactic acid-promoted TGF-\u03b2 signaling pathway in oral squamous cell carcinoma","volume":"19","author":"Jiang","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117376_b0735","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1476-5381.2011.01521.x","article-title":"Anti-tumour effects of small interfering RNA targeting anion exchanger 1 in experimental gastric cancer","volume":"165","author":"Suo","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117376_b0740","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1006\/geno.1997.5055","article-title":"The structural organization of the human Na+\/myo-inositol cotransporter (SLC5A3) gene and characterization of the promoter","volume":"46","author":"Mallee","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.bcp.2025.117376_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101117","article-title":"Beta-adrenergic pathway activation enhances aggressiveness and inhibits stemness in head and neck cancer","volume":"14","author":"Lopes-Santos","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bcp.2025.117376_b0750","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043788","article-title":"Taurine and Creatine Transporters as potential Drug Targets in Cancer Therapy","volume":"24","author":"Stary","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117376_b0755","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3349\/ymj.2017.58.1.27","article-title":"Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer","volume":"58","author":"Sung","year":"2017","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.bcp.2025.117376_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2023.113700","article-title":"SLC9A5 promotes tumor growth and cell motility via ACOX1-mediated peroxisomal fatty acid oxidation","author":"Zheng","year":"2023","journal-title":"Exp Cell Res 430"},{"key":"10.1016\/j.bcp.2025.117376_b0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107270","article-title":"TFE3-SLC36A1 axis promotes resistance to glucose starvation in kidney cancer cells","author":"Lv","year":"2024","journal-title":"J Biol Chem 300"},{"key":"10.1016\/j.bcp.2025.117376_b0770","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12964-018-0243-0","article-title":"SLC12A7 alters adrenocortical carcinoma cell adhesion properties to promote an aggressive invasive behavior","volume":"16","author":"Brown","year":"2018","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bcp.2025.117376_b0775","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.2147\/OTT.S103640","article-title":"Decreased expression of SLC 39A14 is associated with tumor aggressiveness and biochemical recurrence of human prostate cancer","volume":"9","author":"Xu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bcp.2025.117376_b0780","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41598-020-80152-0","article-title":"Highly expressed SLCO1B3 inhibits the occurrence and development of breast cancer and can be used as a clinical indicator of prognosis","volume":"11","author":"Tang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117376_b0785","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41419-022-04692-1","article-title":"An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2025.117376_b0790","doi-asserted-by":"crossref","first-page":"18352","DOI":"10.1038\/s41598-020-75012-w","article-title":"Comprehensive analysis of the expression of SLC30A family genes and prognosis in human gastric cancer","volume":"10","author":"Guo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117376_b0795","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/0008-5472.CAN-15-1862","article-title":"Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth","volume":"76","author":"McIntyre","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117376_b0800","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.803198","article-title":"Identification of a Six-Gene SLC Family Signature with Prognostic Value in patients with Lung Adenocarcinoma","author":"Zhu","year":"2021","journal-title":"Front Cell Dev Biol 9"},{"key":"10.1016\/j.bcp.2025.117376_b0805","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.dmpk.2020.01.008","article-title":"Functional characterization of monocarboxylate transporter 12 (SLC16A12\/MCT12) as a facilitative creatine transporter","volume":"35","author":"Takahashi","year":"2020","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2025.117376_b0810","doi-asserted-by":"crossref","first-page":"22164","DOI":"10.18632\/aging.203502","article-title":"SLCO1B3 promotes colorectal cancer tumorigenesis and metastasis through STAT3","volume":"13","author":"Zhi","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.bcp.2025.117376_b0815","article-title":"A Comprehensive Prognostic and Immune Analysis of SLC41A3 in Pan-Cancer., Front","volume":"10","author":"Liu","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.bcp.2025.117376_b0820","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23312","article-title":"Analysis of lncRNA UCA1-related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma","volume":"34","author":"Zhou","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.bcp.2025.117376_b0825","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1615\/CritRevEukaryotGeneExpr.2021039703","article-title":"Up-Regulation of SLC26A6 in Hepatocellular Carcinoma and its Diagnostic and Prognostic significance","volume":"31","author":"Zhu","year":"2021","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.bcp.2025.117376_b0830","article-title":"KLK10\/LIPH\/PARD6B\/SLC52A3 are promising molecular biomarkers for the prognosis of pancreatic cancer through a ceRNA network","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bcp.2025.117376_b0835","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1038\/s41598-020-64356-y","article-title":"Comprehensive analysis of the SLC16A gene family in pancreatic cancer via integrated bioinformatics","volume":"10","author":"Yu","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117376_b0840","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/1097-0142(20010915)92:6<1577::AID-CNCR1484>3.0.CO;2-H","article-title":"A phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833","volume":"92","author":"Bates","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2025.117376_b0845","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jlcr.3542","article-title":"Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin (JNJ-28431754)","volume":"60","author":"Lin","year":"2017","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1016\/j.bcp.2025.117376_b0850","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1634\/theoncologist.2012-0080","article-title":"A pharmacodynamic study of the P-glycoprotein antagonist CBT-1\u00ae in combination with paclitaxel in solid tumors","volume":"17","author":"Kelly","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.bcp.2025.117376_b0855","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2006.08.1646","article-title":"Dofequidar Fumarate (MS-209) in Combination with Cyclophosphamide, Doxorubicin, and Fluorouracil for patients with Advanced or Recurrent Breast Cancer","volume":"25","author":"Saeki","year":"2007","journal-title":"J. Clin. Oncol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:49:56Z","timestamp":1773136196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225006410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":171,"alternative-id":["S0006295225006410"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117376","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-associated transporters: Molecular drivers and drug delivery gateways","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117376"}}